Lymphoma highlights from ASCO 2025 include data on CAR-T cell therapy, zilovertamab vedotin in relapsed or refractory (R/R) LBCL, and optimal dosing of AFM13 plus AlloNK in R/R Hodgkin lymphoma.

Incorporating brentuximab vedotin into the treatment of advanced-stage classic Hodgkin’s lymphoma improves outcomes in adult and pediatric patients. However, brentuximab vedotin increases the ...

In November 2024, Dave Coulier revealed he was diagnosed with stage 3 non-Hodgkin lymphoma. The former Full House star was a fan-favorite on the show and fans want to know more about his health ...

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma ...